Research programme: anti PD-1 antibodies - Cellectis/MabQuest

Drug Profile

Research programme: anti PD-1 antibodies - Cellectis/MabQuest

Latest Information Update: 05 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellectis; MabQuest
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 16 Mar 2016 Early research in Cancer in France (Parenteral)
  • 16 Mar 2016 Cellectis and MabQuest enter into research collaboration and license agreement to develop monoclonal antibodies targeting PD-1
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top